Dr. Choy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Yawkey 7B
Boston, MA 02114Phone+1 617-724-4000Fax+1 617-643-8744- Is this information wrong?
Summary
- Dr. Edwin Choy is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from NYU School of Medicine and has been in practice 23 years. He specializes in bone and soft tissue sarcoma oncology as well as treatment of chordoma, GIST, giant cell tumor of bone, and desmoid fibromatosis.
For CV see https://www.massgeneral.org/assets/mgh/pdf/cancer-center/edwin-choy-cv2022-public.pdf
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2005
- Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
- New York University School of MedicineClass of 2000
- Yale UniversityBS, Molecular Biophysics and Biochemistry, 1993
Certifications & Licensure
- NH State Medical License 2021 - 2025
- MA State Medical License 2002 - 2025
- ME State Medical License 2021 - 2024
- RI State Medical License 2021 - 2024
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014-2023
- Nominee for the "2013 Brian McGovern Award for Clinical Excellence Massachusetts General Physicians Organization Physician Recognition Dinner, 2013
- Honoree Chawla-Rosenfeld Symposium, 2012
- Join now to see all
Clinical Trials
- PCI-24781 in Combination With Doxorubicin to Treat Sarcoma Start of enrollment: 2009 Feb 01
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Start of enrollment: 2010 Sep 01
- Nilotinib With Radiation for High Risk Chordoma Start of enrollment: 2011 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Liao, Y., Chen, L., Feng, Y., Shen, J., Gao, Y., Mankin, H., Duan, Z., Cote, G., Choy, E., Harmon, D., Hornicek, F.> ;Oncotarget. 2024 Feb 5
- Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Liao, Y., Sassi, S., Halvorsen, S., Feng, Y., Shen, J., Gao, Y., Mankin, H., Duan, Z., Cote, G., Choy, E., Harmon, D., Hornicek, F.> ;Scientific Reports. 2024 Jan 22
- A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.Daniel E McLoughlin, Nicholas Chevalier, Edwin Choy, Gregory M Cote, Xin Gao, Dejan Juric, Kerry L Reynolds> ;The Oncologist. 2023 Dec 11
- Join now to see all
Journal Articles
- CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma CellsEdwin Choy, Francis J Hornicek, Henry Mankin, Cellular Physiology and Biochemistry
- TP53 Mutations Emerge with HDM2 Inhibitor SAR405838 Treatment in De-Differentiated LiposarcomaMark A Dickson, Edwin Choy, Nature
- Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of BoneWojcik J, Rosenberg AE, Bredella MA, Choy E, Nielsen GP, Deshpande V., Am J Surg Pathol., 1/24/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Programmed Cell Death Ligant 1 Expression in ChordomaFeng, Y., Shen, J., Gao, Y., Cote, G., Choy, E., Mankin, H., Hornicek, F., and Duan, Z., ORS (Orthopaedic Research Society) 2015 Annual Meeting, Las Vegas, NV, 1/1/2015
- Expression of PIM1 Kinase in Osteosarcoma and the Clinical SignificanceFeng, Y., Gao, Y., Shen, J., Cote, G., Choy, E., Mankin, H., Hornicek, F., and Duan, Z., ORS (Orthopaedic Research Society) 2015 Annual Meeting, Las Vegas, NV, 1/1/2015
- TP53 Mutations Emerge in Circulating Cell-free DNA Obtained from Patients Undergoing Treatment with the HDM2 Antagonist SAR405838Jung, J., Dickson, M., Schwartz, G., Le Cesne, A., Varga, A., Bahleda, R., Wagner, A., Choy, E., de Jonge, M., Light, M., Lee, JS, Mace, S., and Watters, J, Meeting of the American Society of Clinical Oncology, Chicago, IL, 1/1/2015
- Join now to see all
Lectures
- A 28 Year Old Woman with Back Pain and a Lesion in the Lumbar SpineMGH Cancer Center - 1/1/2015
- Presentation of Research Results SNU Sarcoma SymposiumSeoul National University Hospital (SNUH), Seoul, South Korea - 1/1/2015
- Case Presentation and Discussion of a Pelvic Mucoepithelial CarcinomaBotswana-Harvard AIDS Institute - 1/11/2014
- Join now to see all
Other
- Osteogenic Sarcoma Staging. Medscape ReferenceChoy E
http://emedicine.medscape.com/article/2007306-overview
1/21/2013 - Osteogenic Sarcoma Treatment ProtocolsChoy E
http://emedicine.medscape.com/article/2006667-overview
1/21/2013 - Leading the Fight Against Childhood CancerWGBH Interview with Jordan Weinstein of NPR's Morning Edition
http://www.wgbh.org/articles/Leading-theFight-Against-Childhood-Cancer-6147
1/2/2012 - Join now to see all
Press Mentions
- Sarcoma Highlights from ESMO 2021September 30th, 2021
Professional Memberships
- Member
Hospital Affiliations
- Massachusetts General HospitalBoston, Massachusetts
External Links
- CVhttps://www.massgeneral.org/assets/mgh/pdf/cancer-center/edwin-choy-cv2022-public.pdf
- MGH Profilehttps://www.massgeneral.org/doctors/17884/edwin-choy
- LinkedInhttps://www.linkedin.com/in/edwin-choy-98a8124/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: